Calcimimetics versus parathyroidectomy for treatment of primary hyperparathyroidism: Retrospective chart analysis of a prospective database

Annals of Surgery

Volumn 255, Issue 5, 2012, Pages 981-985

  Keutgen, Xavier M ^a   Buitrago, Daniel ^a   Filicori, Filippo ^a   Kundel, Anna ^a   Elemento, Olivier ^b   Fahey, Thomas J ^a   Zarnegar, Rasa ^a  

^a Department of Surgery   (United States)

^b WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIMIMETIC AGENT; CALCIUM;

AGED; ARTICLE; BONE DENSITY; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FEMUR; FOLLOW UP; HUMAN; MALE; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROIDECTOMY; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; SCORING SYSTEM; SPINE; TREATMENT OUTCOME;

AGED; BONE DENSITY; CALCIMIMETIC AGENTS; CALCIUM; FEMALE; HUMANS; HYPERPARATHYROIDISM, PRIMARY; MALE; MIDDLE AGED; PARATHYROID HORMONE; PARATHYROIDECTOMY; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84859913662     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e31824c5252     Document Type: Article

References (24)

1. Melton LJ III. Epidemiology of primary hyperparathyroidism. J Bone Miner Res. 1991;6(suppl 2):S25-S30; discussion S31-S32.
2. Potts JT, Jr. Consensus development conference. J Bone Miner Res. 1991;6:S9-S13.
3. Biskobing DM. Significance of elevated parathyroid hormone after parathyroidectomy. Endocr Pract. 2010;16:112-117.
4. Nomura R, Sugimoto T, Tsukamoto T, et al. Marked and sustained increase in bone mineral density after parathyroidectomy in patients with primary hyperparathyroidism: a six-year longitudinal study with or without parathyroidectomy in a Japanese population. Clin Endocrinol (Oxf). 2004;60:335-342. (Pubitemid 38297124)
5. Christiansen P, Steiniche T, Brixen K, et al. Primary hyperparathyroidism: effect of parathyroidectomy on regional bone mineral density in Danish patients: a three-year follow-up study. Bone. 1999;25:589-595. (Pubitemid 29469466)
6. Rubin MR, Bilezikian JP, McMahon DJ, et al. The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. J Clin Endocrinol Metab. 2008;93:3462-3470.
7. Silverberg SJ, Shane E, de la Cruz L, et al. Skeletal disease in primary hyperparathyroidism. J Bone Miner Res. 1989;4:283-291. (Pubitemid 19161996)
8. Parfitt AM. Accelerated cortical loss: primary and secondary hyperparathyroidsm. In: Uhthoff H, Stahl E eds. Current Concepts of Bone Fragility. Berlin, Germany: Springer-Verlag; 1986;279-285.
9. Brown EM, Gamba G, Riccardi D, et al. Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid. Nature. 1993;366:575-580. (Pubitemid 24035999)
10. Brown EM, Hebert SC. A cloned extracellular Ca(2+)-sensing receptor: molecular mediator of the actions of extracellular Ca2+ on parathyroid and kidney cells? Kidney Int. 1996;49:1042-1046.
11. Nemeth EF, Steffey ME, Hammerland LG, et al. Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad Sci USA. 1998;95:4040-4045. (Pubitemid 28173250)
12. Peacock M, Bilezikian JP, Klassen PS, et al. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab. 2005;90:135-141. (Pubitemid 40116646)
13. Peacock M, Bolognese MA, BorofskyM, et al. Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a fiveyear study. J Clin Endocrinol Metab. 2009;94:4860-4867.
14. Shoback DM, Bilezikian JP, Turner SA, et al. The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. J Clin Endocrinol Metab. 2003;88:5644-5649. (Pubitemid 38033028)
15. EMEA. [Prescribing Information for Mimpara Web site]. Available at: www.emea.europa.eu/humandocs/PDFs/EPAR/mimpara/H-570-PI-en.pdf. Accessed March 3, 2011.
16. Yen TW, Wilson SD, Krzywda EA, et al. The role of parathyroid hormone measurements after surgery for primary hyperparathyroidism. Surgery. 2006;140:665-672; discussion 672-674.
17. Wuthrich RP, Martin D, Bilezikian JP. The role of calcimimetics in the treatment of hyperparathyroidism. Eur J Clin Invest. 2007;37:915-922. (Pubitemid 350151180)
18. Toro Prieto FJ, Bernal Blanco G, Navarro Garcia M, et al. Calcimimetics and bone mineral density in renal transplant patients with persistent secondary hyperparathyroidism. Transplant Proc. 2009;41:2144-2147.
19. Lien YH, Silva AL, Whittman D. Effects of cinacalcet on bone mineral density in patients with secondary hyperparathyroidism. Nephrol Dial Transplant. 2005;20:1232-1237. (Pubitemid 40862116)
20. Khan A, Grey A, Shoback D. Medical management of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab. 2009;94:373-381.
21. Khan AA, Bilezikian JP, Kung AW, et al. Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab. 2004;89:3319-3325. (Pubitemid 38951898)
22. Parker CR, Blackwell PJ, Fairbairn KJ, et al. Alendronate in the treatment of primary hyperparathyroid-related osteoporosis: a 2-year study. J Clin Endocrinol Metab. 2002;87:4482-4489. (Pubitemid 35247029)
23. Sensipar. R (cinacalcet) prescribing information, Amgen. Available at: http://www.sensipar.com/hcp home.html. Accessed May 2, 2011.
24. Mihai R, Simon D, Hellman P. Imaging for primary hyperparathyroidism-an evidence-based analysis. Langenbecks Arch Surg. 2009;394:765-784.